Unisense FertilTech A/S Signs Million Dollar Deal with Europe’s Largest Infertility Treatment Provider
(Aarhus Denmark, July 1, 2010) After years of work developing an advanced technology aimed at improving treatment in the field of assisted reproduction, Unisense FertiliTech A/S has now received a commercial seal of approval from one of the world’s leading Infertility treatment chains. Equipo IVI, with headquarters in Valencia Spain has 20 clinics worldwide and generates revenue above EUR 100 million.
Equipo IVI has committed to the purchase of additional EmbryoScope™ Monitoring System for use at 7 clinics in Spain, and by the end of September 2010 IVI will have systems running at a total of 10 clinics in Spain. IVI has been using the EmbryoScope™ Embryo Monitoring System at 3 of their locations in Valencia and Alicante for both research and clinical use over the past 12 months with very promising results.
Unisense FertiliTech COO Søren Ankerstjerne comments “We are pleased that IVI, a highly respected worldwide leader in Assisted Reproduction treatment and research, has chosen to implement our technology on a larger scale. This contract confirms the utility of our technology and its potential to improve the quality of patient treatment”.
Unisense FertiliTech A/S was founded in 2003 as a subsidiary of Unisense A/S. The company develops and sells technology and software for improvement of assisted reproduction. It is a research based company which at present participates in various international research projects.
The company has 32 employees and a domicile including own production next to Aarhus University Hospital Skejby.
Increased capital funding for Unisense FertiliTech A/S will help meet demand for new Assisted Reproduction device.
(Aarhus, Denmark, December 14, 2009) Unisense FertiliTech A/S has received a further 1.6 million Euro in capital funding to scale up production and support of the EmbryoScope™ Embryo Monitoring System in order to meet the rapidly growing demand for this promising new technology. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.
During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro. The resulting fertilized eggs are allowed to develop for a period of 2 to 5 days, before the embryologist must select the best potential embryo or embryos to transfer back to the patient. Ideally, a single embryo resulting in a single pregnancy is optimal as multiple pregnancies present risks to both maternal and fetal health.
A major challenge for the embryologist is determining which embryos have the best potential to create a single healthy baby.
The EmbryoScope® Monitoring System allows uninterrupted observation of embryo development in a stable controlled incubation environment. Embryo quality parameters can be assessed and reviewed without the potentially damaging effects of removing the embryo from a stable controlled environment.
CEO Jens Gundersen says they are encouraged with the overwhelming response to the initial sales launch of the instrument, and that with the additional capital, FertiliTech will be able to scale up production to meet the demands of the rapidly expanding interest for the EmbryoScope® Embryo monitoring system.
June 29, 2009
Unisense FertiliTech A/S announces that the EmbryoScope™ Embryo Monitoring System has received CE approval as a class IIa medical device. In addition, Unisense Fertilitech A/S has received the DS/EN ISO13485:2003 and AC:2007 quality system certificate for production, installation and servicing of IVF incubators and related accessories
Francesca Bahr, sales manager at FertiliTech says the CE mark will allow Unisense FertiliTech to market their instrument to Assisted Reproduction clinics across Europe with the goal of improving embryo assessment and to facilitate the larger goal of elective single embryo transfer.
During IVF treatment, multiple oocytes are removed from the patient and fertilized in-vitro. The resulting fertilized eggs are allowed to develop for a period of 2 to 5 days, before the embryologist must select the best potential embryo or embryos to transfer back to the patient. Ideally, a single embryo resulting in a single pregnancy is optimal as multiple pregnancies present risks to both maternal and fetal health.
A major challenge for the embryologist is determining which embryos have the best potential to create a single healthy baby.
The EmbryoScope™ Monitoring System allows uninterrupted observation of embryo development in a stable controlled environment. Embryo quality parameters can be assessed and reviewed without the potentially damaging effects of removing the embryo from a stable controlled environment.
Mette Munch, Director of regulatory affairs at Unisense FertiliTech says she will now set her goal on FDA 510K clearance in order to facilitate marketing to clinics in the United States.
The Announcement of the CE mark coincided with the successful sales launch of the EmbryoScope™ Embryo Monitoring System at the European society of Human reproduction and Embryology in Amsterdam, June 29.July 1 2009
May 26, 2009
Aarhus, Denmark, May 26, 2009 Unisense FertiliTech A/S has recently received a further 2.5 million US in capital funding for the continued certification process and market launch of the EmbryoScope™ Embryo Monitoring System. The capital was invested by LD Pensions and Unisense A/S that continue to own each about 50% of the company.
May 26, 2009
UniSense Fertiltech awarded exclusive license to utilize Reify’s Visible™ Discovery Platform in the development of critical event detection and time-lapse analysis software for ooctyes and embryo development for use with the EmbryoScope™ Embryo Monitoring System, in and IVF clinical setting. Unisense FertiliTech A/S will also receive non-exclusive development rights from Reify for stem cell analysis research with defined exceptions. Under the terms of the agreement Reify receives a combination of annual guaranteed payments and royalties.
